Actively Recruiting

Phase 2
Age: 18Years - 85Years
All Genders
NCT06632613

Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surgery

Led by EnnovaBio · Updated on 2025-01-13

200

Participants Needed

1

Research Sites

68 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The is a two-stage study. Stage 1 is to evaluate the safety, tolerability, PK and PD of ENN0403 in patients at high risk of AKI following elective cardiac surgery requring cardiopulmonary bypass. Stage 2 is to evaluate the efficacy, safety, PK and PD of ENN0403 to prevent and treat AKI after multiple administraions in patients at high risk of AKI following elective cardiac surgery requring cardiopulmonary bypass.

CONDITIONS

Official Title

Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surgery

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to understand and comply with study requirements and provide written informed consent
  • Age 18 to 85 years
  • Male subjects and their fertile female partners must not plan pregnancy during screening and 3 months after last dose; only non-fertile women are eligible
  • Scheduled for cardiac surgery requiring cardiopulmonary bypass, including coronary artery bypass grafting and/or heart valve surgery, aortic root, ascending aorta, or aortic arch surgery
  • At risk for AKI based on specific surgery combinations and risk factors as defined in the protocol
Not Eligible

You will not qualify if you...

  • Received ICD or permanent pacemaker implantation, mechanical ventilation, intra-aortic balloon pump (IABP), left ventricular assist device (LVAD), or other mechanical circulatory aids within 1 week before surgery
  • Cardiopulmonary resuscitation within 14 days prior to screening
  • Abnormal renal function with eGFR less than 20 mL/min/1.73 m2 within 30 days before screening
  • Received renal replacement therapy or had AKI within 30 days before surgery, except transient stage 1 AKI after contrast agent exposure
  • Participation in other clinical trials within the past month
  • Known allergy to investigational drug or any constituents used in the study
  • Intractable hypotension, severe hypoxemia, or other surgical emergencies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhongshan Hospital, Fudan University

Shanghai, China

Actively Recruiting

Loading map...

Research Team

X

Xiaoyu Ma

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here